Physician

Michael J Miedler, MD

According to 2025 Medicare claims, Michael Miedler, MD (NPI: 1548261837) practices infectious disease in the Lexington-Fayette, KY market, with the plurality of this provider's patient population coming from Fayette, KY. This provider's primary affiliated billing organization is LEXINGTON INFECTIOUS DISEASE CONSULTANTS PSC (NPI: 1922158294; TIN: 611178691) and primary practice location at 40504-3742. Miedler is affiliated with the CHI Saint Joseph Health Partners (ACO ID: A4638), participating under the MSSP model.

Miedler's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 288 traditional Medicare patients, billed 87,278 HCPCS/CPT codes, and received $209,625 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 770 prescription claims across 126 beneficiaries totaling $220,631 in drug costs, led by Daptomycin (Daptomycin). 2018 DME data shows 24 claims. Open Payments data shows 14 records totaling $326. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $346,916 to $209,625. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $157,196 and ending at $220,631. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	526	50,711	$346,916
2016	570	84,488	$380,535
2017	519	90,601	$380,017
2018	507	86,100	$377,104
2019	468	95,165	$370,721
2020	408	130,901	$359,344
2021	314	66,641	$248,504
2022	291	50,083	$188,120
2023	292	83,820	$231,275
2024	288	87,278	$209,625

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	91	320	$157,196
2016	139	434	$158,179
2017	132	513	$171,789
2018	123	524	$191,457
2019	117	455	$105,798
2020	104	430	$137,250
2021	110	627	$211,184
2022	100	464	$76,488
2023	108	601	$164,992
2024	126	770	$220,631

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	26	$5,391
2016	N/R	22	$3,228
2017	N/R	N/R	N/R
2018	N/R	24	$755
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	159	202	$120
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	132	493	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	71	129	$63
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	176	1,365	$59
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	93	311	$44

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Daptomycin	Daptomycin	130	821	$97,080
Ertapenem	Ertapenem Sodium	56	359	$38,642
Micafungin	Micafungin Sodium	34	208	$11,763
Cefepime Hcl	Cefepime Hcl	19	163	$8,510
Vancomycin Hcl	Vancomycin Hcl	32	268	$8,269

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$326	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael J. Miedler, MD?

Tedicare shows public-source Medicare data for Michael J. Miedler, MD (NPI 1548261837), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael J. Miedler, MD have ACO affiliation data?

Michael J. Miedler, MD is shown with ACO affiliation data for CHI Saint Joseph Health Partners (MSSP, ACO ID A4638).

What billing organization is linked to Michael J. Miedler, MD?

Michael J. Miedler, MD is linked to LEXINGTON INFECTIOUS DISEASE CONSULTANTS PSC (billing NPI 1922158294) in the available physician profile data.

Does Michael J. Miedler, MD have Open Payments data?

Michael J. Miedler, MD has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.